Nour Aymn Ahmad

Mrs. Nour Aymn Ahmad

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2026 in JMIR AI
Verified
Journal Article
Open access
GAGhufran Alsalloum
Ghufran Alsalloum
YBYara Badr
Yara Badr
Ayman AlzaatrehAyman Alzaatreh
Ayman Alzaatreh
ASAbdulRahim Shamayleh
AbdulRahim Shamayleh
MKMuhammad Kumail
Muhammad Kumail
YHYacine Hadjiat
Yacine Hadjiat
Background: Artificial intelligence (AI) can enhance diagnostic accuracy, efficiency, and decision-making in health care, but real-world impact depends on practitioners’ acceptance and readiness to use AI in clinical workflows. The United Arab Emirates offers a policy-driven context to study these factors, given active national AI strategies and rapid health system digitization. Objective: This study aimed to develop and validate a model explaining how trust, perceptions, perceived risk, and perceived benefit shape practitioners’ acceptance of AI and, in turn, their readiness to implement AI in clinical practice. The model integrates the Technology Acceptance Model, the Unified Theory of Acceptance and Use of Technology, and the Theory of Trust and Acceptance of Artificial Intelligence Technology. Methods: We conducted a cross-sectional online survey of 182 United Arab Emirates–based health care practitioners (physicians, nurses, dentists, and allied health staff). Constructs included trust, perception, perceived risk, perceived benefit, acceptance, and readiness. Knowledge of AI was also assessed using true or false statements. We performed confirmatory factor analysis and structural equation modeling, reporting standard fit indices. The survey adhered to the Checklist for Reporting Results of Internet E-Surveys guidelines, and ethics approval and electronic consent were obtained. Results: Trust was positively associated with perception ( β =.704; P <.001) and perceived benefit ( β =.191; P =.02) and negatively associated with perceived risk ( β =−.301; P <.001). Acceptance was positively associated with trust ( β =.452; P <.001), perception ( β =.459; P <.001), and perceived benefit ( β =.168; P =.002), and negatively associated with perceived risk ( β =−.140; P =.009). Acceptance strongly predicted readiness ( β =.874; P <.001). The model fit indices are standardized root-mean-square residual of 0.068, root-mean-square error of approximation of 0.0913, goodness-of-fit index of 0.802, adjusted goodness-of-fit index of 0.763, and comparative fit index of 0.906. Our knowledge assessment found notable gaps among participants, underscoring a need for education and training. Our study sample was predominantly drawn from Dubai-based health care settings (103/182, 57%) and nursing roles (71/182, 39%); therefore, these findings primarily reflect the Dubai health regulatory environment and nursing workflows and may not generalize to the broader federal health care system across all Emirates. Conclusions: Trust is a central lever for advancing AI acceptance and implementation readiness among the study cohort of United Arab Emirates–based health care practitioners. Implementation programs should prioritize building institutional and technical trust (transparency, safety, and governance), reducing perceived risk (privacy, security, and reliability), and amplifying perceived benefits through hands-on demonstrations and workflow-aligned use cases. Targeted training to close knowledge gaps should accompany policy and organizational measures aligned with national AI strategies to accelerate responsible, clinician-in-the-loop adoption.

14 April 2026 in Journal of Pharmaceutical Policy and Practice
Verified
Journal Article
Open access
NANour Aymn Ahmad
Nour Aymn Ahmad
Rabia HussainRabia Hussain
Rabia Hussain
Diabetes mellitus (DM) is a significant public health issue that requires lifelong management. Effective management requires a comprehensive approach integrating technology and clinical pharmacists into the healthcare team to improve glycemic control, patient knowledge, medication adherence, and quality of life. This study aims to evaluate the impact of a clinical pharmacist-led tele-educational intervention (PharmaTE trial) on glycemic control and patients’ outcomes among patients with type 2 diabetes at a secondary care hospital in Ras Al Khaimah, United Arab Emirates (UAE). A mixed-methods embedded design will be employed, consisting of a randomised controlled trial (RCT) as the quantitative phase and a prospective descriptive qualitative study, a total of 154 adult patients diagnosed with uncontrolled type 2 diabetes, will be recruited and randomly assigned to either the (PharmaTE trial) intervention group (IG), which will receive five tele-education sessions led by a clinical pharmacist, or a control group (CG) receiving standard care. The primary outcome will be improved glycemic control, specifically achieving a target HbA1c level < 6.5% for individuals aged 18–65. Secondary outcomes will include improved diabetes knowledge, medication adherence, and quality of life, assessed using a validated Arabic version of the questionnaires: the Michigan Diabetes Knowledge Tool (MDKT), Morisky Medication Adherence Scale (MMAS), and Diabetes Quality of Life (DQOL). Moreover, the glycemic control will be evaluated by measuring HbA1c levels. Compared to the control group, participants with uncontrolled glycemic levels are anticipated to show improvements in glycemic control, disease knowledge, medication adherence, and quality of life upon completion of the PharmaTE trial. These expected outcomes highlight the importance of adopting innovative, technology-based strategies and integrating clinical pharmacists into multidisciplinary care teams to enhance diabetes management. The PharmaTE intervention may offer an effective model for improving patient engagement, optimising treatment adherence, and ultimately advancing overall diabetes care and outcomes among patients with type 2 diabetes. The study protocol was registered as a clinical trial on ClinicalTrials.gov with the identifier NCT07043816 on June 20, 2025, and it was registered prospectively. Trial registration: ClinicalTrials.gov identifier: NCT07043816.

23 October 2026 in Pharmacy
Verified
Journal Article
Open access
PDF file
Bayan Faisal AbabnehBayan Faisal Ababneh
Bayan Faisal Ababneh
Hisham AlJamalHisham AlJamal
Hisham AlJamal
NANour Aymn Ahmad
Nour Aymn Ahmad
LALouai Alsaloumi
Louai Alsaloumi
Background/Objectives: Telepharmacy refers to the use of telecommunication and digital technologies to provide pharmacy services remotely. Early telepharmacy models were implemented in the early 2000s to extend pharmaceutical care to patients in remote and underserved areas. Evaluating pharmacists’ attitudes, awareness, and perceptions of telepharmacy services is essential to inform policy, training, and implementation guidelines. This review summarizes studies on pharmacists’ attitudes, awareness, or perceptions of telepharmacy services. Methods: A systematic literature search was conducted to identify qualitative and descriptive quantitative studies that reported on the attitudes, awareness, or perceptions of pharmacists toward the practice of telepharmacy services from January 2000 through April 2026. Searches were conducted in PubMed/MEDLINE, Scopus, Web of Science, Embase, and Google Scholar. The review was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis PRISMA guidelines. Results: Eighteen studies met the inclusion criteria, comprising 13 cross-sectional quantitative studies and 5 qualitative studies across 11 countries. Overall, the included studies reported generally favorable attitudes and perceptions toward telepharmacy, although awareness varied across studies and settings. Pharmacists perceived telepharmacy as beneficial for healthcare accessibility, patient counseling, medication management, and continuity of care. Reported barriers included inadequate technological infrastructure, insufficient training, increased workload, reimbursement concerns, and absence of standardized regulations or practice guidelines. Common facilitators included professional education and training, institutional support, interprofessional collaboration, improved technological infrastructure, and clear telepharmacy guidelines. Conclusions: Pharmacists generally reported favorable attitudes and perceptions toward telepharmacy, although awareness and experiences varied across healthcare settings and countries. Addressing technological, educational, organizational, financial, and regulatory barriers may support effective and sustainable integration of telepharmacy into pharmacy practice.